Overview
| Name | HCAbLM · aliases: HCAbLM |
|---|---|
| Full name | Neither the preprint nor the press release gives an expanded name |
| Ambiguous names (not auto-linked) | None |
| Family | Not a family entry. A single model; the group's separate generative HCAb model is a different model and is not merged |
| Organization | Nona Biosciences, HBM Holdings (Harbour BioMed) |
| Organization type | Pharma |
| Country | China, United States |
| Model class | Antibody LM (developability) |
| Domain | Antibodies |
| First release | · paper revision Basis: bioRxiv preprint v1 posted source |
| Other milestones | |
| Latest update | · no later event Basis: Only the v1 preprint exists No later sourced event found (as of 2026-11-16); no new version, code or weights found source The most recent sourced event, not a claim that nothing changed since. |
| Status | Active · First released 2026-09; no later version yet |
| Openness | Code: Unclear Weights: Unclear The press release and preprint page do not say whether weights or code are public |
| Benchmarks reported | 0 counted · none of the 44 |
| Wet-lab validation | None recorded |
| Unverified fields | † open_status.code, open_status.weights, training_data.a_public |
| As of | 2026-11-17 |
What it does
A 366M-parameter language model that learns only the sequence grammar of fully human heavy-chain-only antibodies (HCAbs); the preprint says HCAbs differ from conventional human VH mainly in CDR1/2, CDR3 architecture and parts of the framework. Frozen representations are transferred to SEC purity, HIC behaviour and thermal stability. It is not a structure or design model, unlike IgGM or RFantibody; its comparators are general and antibody language models such as ESM3.
Benchmarks reported
None of the 44 benchmarks. This model is on the zero-pairing list.
How it evaluates itself: Sequence distribution analysis; Frozen-embedding transfer; Press-release baseline claim
Other evaluations (outside the 44)
- Sequence distribution analysis (Own task set) Self-reported: Compares HCAb and conventional human VH sequences; shifts concentrate in CDRs and some framework regions
- Frozen-embedding transfer to developability (Own task set) Self-reported: Predicts SEC purity, HIC behaviour and thermal stability with grouped internal validation and retrospective cross-project evaluation, all at the developer
- Press-release baseline claim (Comparison against baselines only) Self-reported: Claims to beat IgLM, AbLang and a 6B-parameter ESM model on SEC and HIC; no numbers and the dataset is unnamed
- FLAb and GDPa1 (Public benchmark not among the 44) Self-reported: Not pairings: the FLAb2 model list does not include it, and the public evaluation in the press release is unnamed and cannot be taken as GDPa1
Developers report: a 366M model trained on 31.8M fully human HCAb sequences represents developability better than larger general or antibody language models.
Independent evidence: No independent evidence found. Only the press release and preprint exist; no third-party evaluation found
Training data
Group in Figure 7: Own wet-lab training data.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Not disclosed | Whether public data were mixed in is not disclosed source |
| b. Private or licensed data | No | source |
| c. Own wet-lab data used for training | Yes | Immune repertoires from the company's transgenic mouse platform: 73 immunised mice, 31.8M fully human HCAb sequences source |
| d. Wet lab used only for validation | Yes | SEC, HIC and thermal-stability measurements are used for transfer evaluation source |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: Nona Biosciences was set up in 2022-11 as a wholly owned subsidiary of HBM Holdings (Harbour BioMed, HKEX 02142), offering discovery and preclinical services up to IND; at launch the group said its transgenic mouse platform had been used by over 50 companies and institutions.
- Funding: No separate funding for Nona; the group reported about $158M total 2025 revenue (annual results release), and the 2025-03 AstraZeneca deal included a $105M equity investment.
- Products and partnerships: Products include H2L2 and HCAb transgenic mouse platforms and the Hu-mAtrIx AI discovery platform; in 2025 the group had deals with AstraZeneca, Otsuka, Pfizer, Bristol Myers Squibb and others; a separate generative HCAb model was announced in 2025-10.
- Related models: IgGM / IgGM-FM, RFantibody, ESM3
Reading notes
- The only antibody language model on the site trained on a private transgenic-mouse repertoire; the data are distinctive but there is no results table to compare.
- The ESM comparator is named only in press-release wording; the actual model should be checked in the preprint.
- FLAb2 and GDPa1 are the public tests it most needs; worth following up.
- Weight availability is unstated, so it cannot be reproduced externally.
Caveats
- Comparison claims come from a press release with no numbers and an unnamed dataset.
- All developability evaluation was done inside the developer.
- None of the four added antibody benchmarks on the site has a public score for it.
Sources
- bioRxiv preprint (preprint)
- Company press release (press)
- Nona launch press release (press)
- Group 2025 annual results release (press)
- AstraZeneca collaboration press release (press)
- FLAb2 paper (third-party paper)
Corrections
None recorded.
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-17.